MedinCell: reporting of the Annual General Meeting
13 Setembro 2023 - 2:30AM
Business Wire
Adoption of all the proposed resolutions, except for the 34th
and 36th resolutions, as recommended by the Management
Board
Announcement of the departure of Jaime Arango, Chief
Financial Officer, replaced by Stéphane Postic
Regulatory News:
MedinCell's (Paris:MEDCL) Ordinary Annual and Extraordinary
General Meeting was held on September 12, 2023, at the company's
headquarters (3 rue des Frères Lumière, 34830 Jacou). It was
chaired by Mr. Anh Nguyen, Chairman of MedinCell's Supervisory
Board.
With a quorum of 62.70% the shareholders have adopted the
resolutions proposed by the Management Board, including the
approval of the annual consolidated accounts for exercise ended
March 31, 2023, the remuneration policy applicable to the Chairman
and members of the management board, to the Chairman and the
members of the Supervisory Board as well as financial delegations
granted to the management Board.
The General Meeting also renewed the mandates of four members of
the Supervisory Board: Mr. Philippe Guy, Ms. Tone Kvåle, Ms.
Virginie Lleu and Mr. Anh Nguyen.
As recommended by the Management Board, resolutions 34 and 36
were rejected.
The replay of the general meeting and the detailed voting
results will soon be available on the MedinCell website.
MedinCell has also announced that its Chief Financial Officer
and member of the Management Board, Jaime Arango, will leave the
Company on September 27 to pursue other professional opportunities.
He will be replaced by Stéphane Postic during a transition period.
The company will take advantage of this period to adapt the
financial and capital markets functions to its new challenges.
Graduated from EM Lyon, Stéphane Postic has more than 25 years
of experience in finance, including 20 years in supporting
biotechnology companies, including Genfit (Euronext: GNFT), Da
Volterra, and Egle Therapeutics. He managed corporate finance,
participated in financing and IPO operations and notably interacted
with the European Investment Bank.
"I would like to thank Jaime for his commitment and contribution
to MedinCell's success. He supported the Company through its IPO
and the commercialization of our first product UZEDY,” said
Christophe Douat, Chairman of MedinCell's Management Board.
“MedinCell has entered a new era that will require strengthening
our financial and capital markets functions to adapt them to the
next stage of our growth. Welcome to Stéphane, who will give
MedinCell the full benefit of his experience.”
About MedinCell
MedinCell is a commercial-stage technology pharmaceutical
company developing long-acting injectable drugs in many therapeutic
areas. Our innovative treatments aim to guarantee compliance with
medical prescriptions, to improve the effectiveness and
accessibility of medicines, and to reduce their environmental
footprint. They combine already known and used active ingredients
with our proprietary BEPO® technology which controls the delivery
of a drug at a therapeutic level for several days, weeks or months
from the subcutaneous or local injection of a simple deposit of a
few millimeters, entirely bioresorbable. The first treatment based
on BEPO technology, intended for the treatment of schizophrenia,
was approved by the FDA in April 2023, and is now distributed in
the United States by Teva under the name UZEDY™ (BEPO technology is
licensed to Teva under the name SteadyTeq™).
We collaborate with leading pharmaceutical companies and
foundations to improve global health through new treatment options.
Based in Montpellier, MedinCell currently employs more than 140
people representing more than 25 different nationalities.
UZEDY™ and SteadyTeq™ are trademarks of Teva
Pharmaceuticals.
This press release is for information purposes only. The
information contained herein does not constitute an offer to sell
or a solicitation of an offer to buy or subscribe for the Company's
shares in any jurisdiction, in particular in France. Similarly,
this press release does not constitute investment advice and should
not be treated as such. It is not related to the investment
objectives, financial situation, or specific needs of any
recipient. It should not deprive the recipients of the opportunity
to exercise their own judgment. All opinions expressed in this
document are subject to change without notice. The distribution of
this press release may be subject to legal restrictions in certain
jurisdictions. Persons who come to know about this press release
are encouraged to inquire about, and required to comply with, these
restrictions.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230912644106/en/
David Heuzé - Head of Communications
david.heuze@medincell.com / +33 (0)6 83 25 21 86
Investor Relations France Louis-Victor
Delouvrier/Alban Dufumier medincell@newcap.eu / +33 (0)1 44 71
94 94
Media Relations Nicolas Mérigeau
medincell@newcap.eu / +33 (0)1 44 71 94 94
Head of US Strategy – Investor Relations Grace Kim
grace.kim@medincell.com / +1 (646) 991-4023
Medincell (EU:MEDCL)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Medincell (EU:MEDCL)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024